Chris DeMuth Jr.
Value, event-driven, arbitrage, hedge fund manager

3 Reasons Why Sanofi Rights (GCVRZ) Could Return 50% This Year

SummarySeveral years ago, we were shareholders of the biotechnology company Genzyme, which was purchased at a significant premium by Sanofi, the large French pharma company. The purchase price included a right, which still publicly trades under the ticker "GCVRZ." The right is to payments based...
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason, less the minimum required payment - the cost of a one day pass.